Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Recent Study: PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Current and Future Players


Print article Print article
2013-12-09 13:09:52 - Fast Market Research recommends "PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Current and Future Players" from GlobalData, now available

GlobalData has released its pharma report, "PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Systemic Lupus Erythematosus and Lupus Nephritis Market. The report identifies and analyses the key companies shaping and driving the global Systemic Lupus Erythematosus and Lupus Nephritis market. The report provides insight into the competitive Systemic Lupus Erythematosus and Lupus Nephritis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Full Report Details at
- www.fastmr.com/prod/752929_pharmapoint_systemic_lupus_erythemato ..

Scope

* Investigation of current and future

market competition for Systemic Lupus Erythematosus and Lupus Nephritis
* Competitor assessment
* Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
* Strategic assessment of the Systemic Lupus Erythematosus and Lupus Nephritis sector through market impact analysis, future market scenario and company analysis

Reasons to Get this Report

* Gain a high level view of the trends shaping and driving the Systemic Lupus Erythematosus and Lupus Nephritis Market
* Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
* Create an effective counter-strategy to gain a competitive advantage against those currently in the market
* What's the next big thing in the global Systemic Lupus Erythematosus and Lupus Nephritis market landscape? Identify, understand and capitalize

Report Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Market Outlook
3.1 Global Markets
3.1.1 Forecast
3.1.2 Drivers and Barriers - Global Issues
4 Current and Future Players
4.1 Overview
4.2 Trends in Corporate Strategy
4.3 Company Profiles
4.3.1 GlaxoSmithKline
4.3.2 Roche
4.3.3 UCB
4.3.4 Eli Lilly and Company
4.3.5 Bristol-Myers Squibb
4.3.6 Anthera Pharmaceuticals
4.3.7 ImmuPharma
4.3.8 Merck Serono
5 Appendix
5.1 Bibliography
5.2 Abbreviations
5.3 Methodology
5.4 Forecasting Methodology
5.4.1 Diagnosed SLE and LN Patients
5.4.2 Percent Drug-Treated Patients
5.4.3 Drugs Included in Each Therapeutic Class
5.4.4 General Pricing Assumptions
5.4.5 Generic Erosion
5.5 Physicians and Specialists Included in this Study
5.6 Primary Research - Prescriber Survey
5.7 About the Authors
5.7.1 Analysts
5.7.2 Global Head of Healthcare
5.8 About GlobalData
5.9 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Global Sales Forecasts ($m) for SLE, 2012-2022
Table 2: Global Sales Forecasts ($m) for LN, 2012-2022
Table 3: SLE and LN Market - Global Drivers and Barriers, 2012-2022
Table 4: Key Companies in the SLE and LN Market, 2013
Table 5: GlaxoSmithKline's SLE and LN Portfolio Assessment, 2013
Table 6: GlaxoSmithKline SWOT Analysis, 2013
Table 7: Roche's SLE and LN Portfolio Assessment, 2013
Table 8: Roche SWOT Analysis, 2013
Table 9: UCB's SLE and LN Portfolio Assessment, 2013
Table 10: UCB SWOT Analysis, 2013
Table 11: Eli Lilly and Company's SLE and LN Portfolio Assessment, 2013
Table 12: Eli Lilly and Company SWOT Analysis, 2013
Table 13: BMS' SLE and LN Portfolio Assessment, 2013
Table 14: BMS SWOT Analysis, 2013
Table 15: Anthera Pharmaceuticals' SLE and LN Portfolio Assessment, 2013
Table 16: Anthera Pharmaceuticals SWOT Analysis, 2013
Table 17: ImmuPharma's SLE and LN Portfolio Assessment, 2013
Table 18: ImmuPharma SWOT Analysis, 2013
Table 19: Merck Serono's SLE and LN Portfolio Assessment, 2013
Table 20: Merck Serono SWOT Analysis, 2013
Table 21: Number of Physicians Surveyed by Country

List of Figures

1.2 List of Figures
Figure 1: Global Sales for SLE and LN by Region, 2012-2022
Figure 2: Sales for SLE in the Seven Major Markets by Drug Class According to Market Value and Volume, 2012-2022
Figure 3: Sales for LN in the Seven Major Markets by Drug Class According to Market Value and Volume, 2012-2022
Figure 4: Company Portfolio Gap Analysis in SLE and LN, 2012-2022

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com